Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.4 - $0.63 $94,925 - $149,507
-237,313 Reduced 24.23%
742,287 $319,000
Q2 2023

Aug 14, 2023

SELL
$0.51 - $0.67 $75,021 - $98,557
-147,100 Reduced 13.06%
979,600 $538,000
Q1 2023

May 15, 2023

BUY
$0.6 - $0.91 $229,020 - $347,347
381,700 Added 51.23%
1,126,700 $743,000
Q4 2022

Feb 14, 2023

BUY
$0.48 - $5.33 $357,600 - $3.97 Million
745,000 New
745,000 $469,000

Others Institutions Holding TIL

About Instil Bio, Inc.


  • Ticker TIL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,694,000
  • Market Cap $8.8B
  • Description
  • Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...
More about TIL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.